Since the approved Septin9 methylation assay detects only one CpG-rich region, we hypothesized that a new assay simultaneously detecting two CpG-rich subregions in CRC could enhance sensitivity, especially for samples with very low abundance of circulating tumor DNA (ctDNA) from patients with early-stage disease. Here, SEPTIN9 is linked to neoplasm.